Top

Published in:

01-03-2012 | Original Article

Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders

Authors: Minoru Yoshida, Kazuo Tamura, Masahiro Imamura, Yoshiro Niitsu, Takeshi Sasaki, Akio Urabe, Kazuma Ohyashiki, Tomoki Naoe, Akihisa Kanamaru, Mitsune Tanimoto, Tohru Masaoka

Published in: Annals of Hematology | Issue 3/2012

Abstract

This prospective multicenter study was performed to clarify the efficacy and safety of micafungin (MCFG) as an empirical antifungal therapy for suspected fungal infection in patients with hematological disorders and neutropenia. Three hundred and eighty-eight patients were enrolled; 151 patients with possible fungal infection diagnosed by radiological imaging or serological testing and 237 patients with refractory fever were included in this study. The mean dose and duration of treatment with MCFG were 154.6 mg/day and 14.0 days, respectively. The clinical response rate for patients with possible fungal infection and refractory fever was 60.1% and 65.3%, respectively. Even in persistent neutropenic patients with a neutrophil count of <500/μL throughout the MCFG treatment, the clinical response rate was 46.9%. Ninety-one drug-related adverse events (DAEs) were observed in 56 patients (14.4%) and 9 serious DAEs were observed in 6 patients (1.5%). Neither daily dose nor duration of MCFG treatment affected the incidence of DAEs. It was confirmed that MCFG has adequate clinical efficacy and is safe for the treatment of suspected fungal infections in patients with hematological disorders and neutropenia.

Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE et al (2002) Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRef

Wingard JR (2004) Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 39:S38–S43PubMedCrossRef

Tomishima M, Ohki H, Yamada A, Takasugi H, Maki K et al (1999) FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot (Tokyo) 52:674–676

Hatano K, Morishita Y, Nakai T, Ikeda F (2002) Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) 55:219–222

Chandrasekar PH, Sobel JD (2006) Micafungin: a new echinocandin. Clin Infect Dis 42:1171–1178PubMedCrossRef

Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K et al (2000) In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44:57–62PubMedCrossRef

Nakai T, Uno J, Otomo K, Ikeda F, Tawara S et al (2002) In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 48:78–81PubMedCrossRef

Ikeda F, Wakai Y, Matsumoto S, Maki K, Watabe E et al (2000) Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 44:614–618PubMedCrossRef

Matsumoto S, Wakai Y, Nakai T, Hatano K, Ushitani T et al (2000) Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother 44:619–621PubMedCrossRef

10.

Maesaki S, Hossain MA, Miyazaki Y, Tomono K, Tashiro T et al (2000) Efficacy of FK463, a 1, 3-β-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob Agents Chemother 44:1728–1730PubMedCrossRef

11.

Ikeda F, Tanaka S, Ohki H, Matsumoto S, Maki K et al (2007) Role of micafungin in the antifungal armamentarium. Curr Med Chem 14:1263–1275PubMedCrossRef

12.

Kohno S, Masaoka T, Yamaguchi H, Mori T, Urabe A et al (2004) A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 36:372–379PubMedCrossRef

13.

de Wet NT, Bester AJ, Viljoen JJ, Filho F, Suleiman JM et al (2005) A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 21:899–907PubMedCrossRef

14.

de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF et al (2004) A randomized, double-blind, parallel-group, dose–response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39:842–849PubMedCrossRef

15.

Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C et al (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519–1527PubMedCrossRef

16.

Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D et al (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45:883–893PubMedCrossRef

17.

Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP et al (2008) Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 46:327–360PubMedCrossRef

18.

Fujita H, Yoshida M, Miura K, Sano T, Kito K et al (2009) Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan adult leukemia study group. Int J Hematol 90:191–198PubMedCrossRef

19.

Ishikawa T, Takata T, Tomoyose T, Masuda M, Nakachi S et al (2006) The efficacy of micafungin as an empiric therapy for febrile neutropenic patients refractory to antibacterial agents. Jpn J Chemother 54:125–128

20.

Yanada M, Kiyoi H, Murata M, Suzuki M, Iwai M et al (2006) Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 45:259–264PubMedCrossRef

21.

Toubai T, Tanaka J, Ota S, Shigematsu A, Shono Y et al (2007) Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med 46:3–9PubMedCrossRef

22.

Tamura K, Urabe A, Yoshida M, Kanamaru A, Kodera Y et al (2009) Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma 50:92–100PubMedCrossRef

23.

Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E et al (2010) Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther 32:637–648PubMedCrossRef

24.

Goto N, Hara T, Tsurumi H, Ogawa K, Kitagawa J et al (2010) Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol 85:872–876PubMedCrossRef

25.

Park JS, Kim DH, Choi CW, Jeong SH, Choi JH et al (2010) Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases. Acta Haematol 124:92–97PubMedCrossRef

26.

Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14PubMedCrossRef

27.

ICH Harmonised Tripartite Guideline, Current step 4 version, dated 27 October 1994: Clinical Safety Data Management: definitions and Standards for Expedited Reporting E2A. http://www.ich.org/LOB/media/MEDIA436.pdf. Accessed: October 1994

28.

Maertens J, Theunissen K, Verhoef G et al (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41:1242–1250PubMedCrossRef

29.

Cordonnier C, Pautas C, Maury S et al (2009) Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48:1042–1051PubMedCrossRef

30.

Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, National Institute of Allergy and Infectious Diseases Mycoses Study Group (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764–771PubMedCrossRef

31.

Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP et al (2001) Itraconazole Neutropenia Study Group. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann Intern Med 135:412–422PubMed

32.

Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J et al (2002) National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234PubMedCrossRef

33.

Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391–1402PubMedCrossRef

34.

Obayashi T, Yoshida M, Mori T, Goto H, Yasuoka A et al (1995) Plasma 1,3-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 345:17–20PubMedCrossRef

35.

de Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821PubMedCrossRef

36.

Yoshida M (2006) Usefulness of determination of β-D-glucan in the diagnosis of deep mycosis—experience in Japan. Med Mycol 44(Sup 1):S185–S189CrossRef

Title: Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders
Authors: Minoru Yoshida
Kazuo Tamura
Masahiro Imamura
Yoshiro Niitsu
Takeshi Sasaki
Akio Urabe
Kazuma Ohyashiki
Tomoki Naoe
Akihisa Kanamaru
Mitsune Tanimoto
Tohru Masaoka
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 3/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-011-1316-y

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis

Association between acute lymphoblastic leukemia (ALL) and der(8;9)(q10;q10): a novel case of double der(8;9) in Ph+ adult B cell ALL

Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast

Lenalidomide is active for extramedullary disease in refractory multiple myeloma

Mimicry of hydroxyurea-induced leg ulcer by distal vena saphena parva insufficiency

Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page